US Bancorp’s Cardiff Oncology CRDF Stock Holding History

US Bancorp’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.04K	Hold	3,109	–	–	﹤0.01%	3715
2026 Q1	$5.04K	Hold	3,109	–	–	﹤0.01%	3566
2025 Q4	$8.74K	Hold	3,109	–	–	﹤0.01%	3379
2025 Q3	$6.41K	Hold	3,109	–	–	﹤0.01%	3460
2025 Q2	$9.79K	Hold	3,109	–	–	﹤0.01%	3433
2025 Q1	$9.76K	Hold	3,109	–	–	﹤0.01%	3441
2024 Q4	$13.5K	Hold	3,109	–	–	﹤0.01%	3304
2024 Q3	$8.3K	Buy	3,109 +3,000	+2,752%	+$7.09K	﹤0.01%	3425
2024 Q2	$242	Hold	109	–	–	﹤0.01%	3902
2024 Q1	$582	Hold	109	–	–	﹤0.01%	3848
2023 Q4	$161	Hold	109	–	–	﹤0.01%	3911
2023 Q3	$152	Hold	109	–	–	﹤0.01%	3921
2023 Q2	$160	Hold	109	–	–	﹤0.01%	3929
2023 Q1	$180	Hold	109	–	–	﹤0.01%	4028
2022 Q4	$153	Hold	109	–	–	﹤0.01%	4079
2022 Q3	$0	Hold	109	–	–	﹤0.01%	4079
2022 Q2	$0	Hold	109	–	–	﹤0.01%	4095
2022 Q1	$0	Hold	109	–	–	﹤0.01%	4076
2021 Q4	$1K	Hold	109	–	–	﹤0.01%	3967
2021 Q3	$1K	Sell	109 -47	-30%	-$295	﹤0.01%	3962
2021 Q2	$1K	Buy	156 +47	+43%	+$399	﹤0.01%	3897
2021 Q1	$1K	Buy	+109	New	+$1.32K	﹤0.01%	3777
2018 Q4	–	Sell	-125	Closed	-$1K	–	3597
2018 Q3	$1K	Buy	+125	New	+$592	﹤0.01%	3553

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

US Bancorp's CRDF Position: Q2 2026 in Review

US Bancorp held its Cardiff Oncology (CRDF) position steady in Q2 2026 at 3,109 shares worth $4.04K. The position accounts for ﹤0.01% of the portfolio, ranked #3715.

US Bancorp first reported a position in CRDF in Q3 2018 and has held it in 23 quarters since. The position peaked at $13.5K in Q4 2024. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

US Bancorp held 3,109 shares of Cardiff Oncology worth $4.04K as of Q2 2026.
US Bancorp left its Cardiff Oncology share count unchanged in Q2 2026.
Cardiff Oncology made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3715 holding.
US Bancorp first reported a position in Cardiff Oncology in Q3 2018 and has held it in 23 quarters since.
US Bancorp's Cardiff Oncology position peaked at $13.5K in Q4 2024.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.